<?xml version="1.0" encoding="UTF-8"?>
<XML><RECORDS>
<RECORD>
	<REFERENCE_TYPE>31</REFERENCE_TYPE>
	<AUTHORS>
		<AUTHOR>Martineau, L. C.</AUTHOR>
		<AUTHOR>Couture, A.</AUTHOR>
		<AUTHOR>Spoor, D.</AUTHOR>
		<AUTHOR>Benhaddou-Andaloussi, A.</AUTHOR>
		<AUTHOR>Harris, C.</AUTHOR>
		<AUTHOR>Meddah, B.</AUTHOR>
		<AUTHOR>Leduc, C.</AUTHOR>
		<AUTHOR>Burt, A.</AUTHOR>
		<AUTHOR>Vuong, T.</AUTHOR>
		<AUTHOR>Mai Le, P.</AUTHOR>
		<AUTHOR>Prentki, M.</AUTHOR>
		<AUTHOR>Bennett, S. A.</AUTHOR>
		<AUTHOR>Arnason, J. T.</AUTHOR>
		<AUTHOR>Haddad, P. S.</AUTHOR>
	</AUTHORS>
	<YEAR>2006</YEAR>
	<TITLE>Anti-diabetic properties of the Canadian lowbush blueberry Vaccinium angustifolium Ait</TITLE>
	<SECONDARY_TITLE>Phytomedicine</SECONDARY_TITLE>
	<VOLUME>13</VOLUME>
	<NUMBER>9-10</NUMBER>
	<PAGES>612-23</PAGES>
	<DATE>Nov</DATE>
	<ISBN>0944-7113 (Print)</ISBN>
	<ACCESSION_NUMBER>16979328</ACCESSION_NUMBER>
	<KEYWORDS>
		<KEYWORD>Plant Extracts/chemistry/pharmacology</KEYWORD>
		<KEYWORD>Mice</KEYWORD>
		<KEYWORD>Lipid Metabolism/drug effects</KEYWORD>
		<KEYWORD>Insulin/metabolism</KEYWORD>
		<KEYWORD>Hypoglycemic Agents/analysis/*pharmacology</KEYWORD>
		<KEYWORD>Glucose/metabolism/toxicity</KEYWORD>
		<KEYWORD>Deoxyglucose/metabolism</KEYWORD>
		<KEYWORD>Cytoprotection/drug effects</KEYWORD>
		<KEYWORD>Cell Proliferation/drug effects</KEYWORD>
		<KEYWORD>Cell Line</KEYWORD>
		<KEYWORD>Blueberry Plant/*chemistry</KEYWORD>
		<KEYWORD>Animals</KEYWORD>
		<KEYWORD>3T3 Cells</KEYWORD>
	</KEYWORDS>
	<ABSTRACT>Incidence of type II diabetes is rapidly increasing worldwide. In order to identify complementary or alternative approaches to existing medications, we studied anti-diabetic properties of Vaccinium angustifolium Ait., a natural health product recommended for diabetes treatment in Canada. Ethanol extracts of root, stem, leaf, and fruit were tested at 12.5 microg/ml for anti-diabetic activity in peripheral tissues and pancreatic beta cells using a variety of cell-based bioassays. Specifically, we assessed: (1) deoxyglucose uptake in differentiated C2C12 muscle cells and 3T3-L1 adipocytes; (2) glucose-stimulated insulin secretion (GSIS) in beta TC-tet pancreatic beta cells; (3) beta cell proliferation in beta TC-tet cells; (4) lipid accumulation in differentiating 3T3-L1 cells; (5) protection against glucose toxicity in PC12 cells. Root, stem, and leaf extracts significantly enhanced glucose transport in C2C12 cells by 15-25% in presence and absence of insulin after 20 h of incubation; no enhancement resulted from a 1 h exposure. In 3T3 cells, only the root and stem extracts enhanced uptake, and this effect was greater after 1 h than after 20 h; uptake was increased by up to 75% in absence of insulin. GSIS was potentiated by a small amount in growth-arrested beta TC-tet cells incubated overnight with leaf or stem extract. However, fruit extracts were found to increase 3H-thymidine incorporation in replicating beta TC-tet cells by 2.8-fold. Lipid accumulation in differentiating 3T3-L1 cells was accelerated by root, stem, and leaf extracts by as much as 6.5-fold by the end of a 6-day period. Stem, leaf, and fruit extracts reduced apoptosis by 20-33% in PC12 cells exposed to elevated glucose for 96 h. These results demonstrate that V. angustifolium contains active principles with insulin-like and glitazone-like properties, while conferring protection against glucose toxicity. Enhancement of proliferation in beta cells may represent another potential anti-diabetic property. Extracts of the Canadian blueberry thus show promise for use as a complementary anti-diabetic therapy.</ABSTRACT>
	<NOTES>Journal ArticleResearch Support, Non-U.S. Gov'tGermanyinternational journal of phytotherapy and phytopharmacology</NOTES>
	<URL>http://www.ncbi.nlm.nih.gov/entrez/query.fcgi?cmd=Retrieve&amp;db=PubMed&amp;dopt=Citation&amp;list_uids=16979328</URL>
</RECORD>
</RECORDS></XML>